Office: 3501 Terrace St, 529 Salk Hall
Personal Website: www.cbligand.org/xielab/
Xiang-Qun (Sean) Xie received his Pharmacy B. S. degree in 1982 from the Second Military Medical University in Shanghai, China; Ph.D. in Medicinal Chemistry from the School of Pharmacy, University of Connecticut, 1993; and followed by a Biophysics Post-doctoral training at MIT Francis Bitter National Magnet Laboratory. In addition, he obtained Executive MBA degree in 2003. Currently, Xie is a tenured Professor of Pharmaceutical Sciences and Drug Discovery Institute. He is the Principal Investigator of an integrated research laboratory, consisting of CompuGroup, BioGroup and ChemGroup (www.CBLigand.org/XieLab) and also a Founding Director of Computational Chemical Genomics Screening (CCGS) Center (www.CBLigand.org/CCGS). Xie is co-PI/core director of the NIH funded Pittsburgh Center for Chemical Methodologies & Library Development and NCI/SAIC funded UP Center for Diversity Chemistry. He was co-PI of the NIH Pittsburgh Molecular Library Screening Center. He also holds joint faculty positions at the Departments of Computational Biology and Structural Biology, and Pitt Cancer Institute MT/DD Program. Before he joined Pitt, he was an Associate Professor and a Founding Director of Pharmacoinformatics Research Center in the College of Pharmacy at University of Houston Texas. He held several joint faculty positions at the Institute for Molecular Design (MDL), Texas Learning Computing Center (TLCC), and the Keck Center for Computational & Structural Biology, served as an Advisory Committee Member for the NIH Pharmacoinformatics Training Program at Houston Gulf Coast Consortium (GCC), and was a Director of the Chemistry Coordinating Unit for GCC-Chemical Genomics Screening Center. Prior to UH, Dr. Xie was a Director of the IMS NMR Lab and a joint faculty member of the School of Pharmacy at the University of Connecticut for over 10 years. Dr. Xie is an expert in Medicinal Chemistry, Computational Chemistry/Biology and Biophysics with research focuses on GPCR chemical genomics, in-silico design/cheminformatics virtual screening method development, medicinal chemistry synthesis and recombinant GPCR membrane protein NMR structural biology.